Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
Overview
Know Labs Inc is a cutting-edge medical diagnostic company that specializes in the development of non-invasive testing technologies using proprietary Bio-RFID and ChromaID systems. These technologies leverage electromagnetic energy to capture the unique signature of substances, enabling the detection and identification of biomarkers without the need for conventional invasive procedures. By driving innovation in the field of healthcare diagnostics, Know Labs is committed to providing alternatives that enhance patient experience and streamline clinical operations.
Core Technologies and Innovations
Know Labs Inc has developed two main technologies that define its product offerings:
- Bio-RFID Technology: This technology uses electromagnetic signals to record distinct bio-signatures from various substances, allowing for accurate identification and authentication. It offers a non-invasive approach, minimizing discomfort while delivering precise diagnostic information.
- ChromaID Technology: Utilizing advanced spectral analysis, ChromaID captures the chromatic signature of materials, facilitating their detection and verification in a manner that bypasses traditional, more invasive methods.
These innovations not only represent significant advancements in diagnostic testing but also hold the potential to redefine standard practices within the medical field.
Applications in Medical Diagnostics
The technologies developed by Know Labs Inc are applicable to a wide range of diagnostic scenarios. A primary focus is on the development of wearable devices that integrate these technologies, such as non-invasive blood glucose monitors. This approach aims to eliminate the need for traditional fingerstick testing, thereby reducing patient discomfort and improving adherence to monitoring regimens. The practical applications of such tools extend beyond diabetes management to potentially encompass a variety of diagnostic uses where traditional methods are cumbersome or invasive.
Market Position and Industry Context
Operating in the competitive healthcare technology and medical diagnostics sector, Know Labs Inc carves out its niche by offering significantly disruptive non-invasive testing methods. Its emphasis on using electromagnetic energy to capture biomolecular signatures sets the company apart from traditional lab-based diagnostic systems. In doing so, Know Labs not only addresses critical challenges such as patient discomfort and procedural inefficiencies but also reinforces its position as a specialist in innovative diagnostic solutions within a rapidly evolving market.
Business Model and Revenue Considerations
The company’s business model centers on the research, development, and commercialization of its proprietary diagnostic technologies. Revenue generation is primarily achieved through the sales and marketing of medical devices and integrated diagnostic systems, along with potential licensing of its technologies to strategic partners. This model allows Know Labs Inc to expand the reach of its innovations throughout various segments of the healthcare industry, further solidifying its role as a transformative force in diagnostics.
Competitive Advantages and Industry Impact
Know Labs Inc distinguishes itself through its commitment to non-invasive, patient-friendly diagnostics. The use of sophisticated electromagnetic energy-based techniques provides an alternative to traditional, often cumbersome laboratory tests. This focus on innovation not only improves the accuracy and speed of diagnosis but also positions the company as a thought leader in the development of next-generation medical devices. The combination of its unique technologies and a strategically diversified product portfolio has the potential to influence the broader healthcare landscape significantly.
Detailed Technological and Clinical Insights
Understanding the technical nuances of Know Labs Inc's offerings requires an appreciation of both the scientific and practical aspects of its technologies. The Bio-RFID system relies on a precise interaction between electromagnetic waves and biological tissues, capturing signatures that are both unique and replicable. Similarly, the ChromaID system applies principles of spectral analysis to differentiate between subtle variations in material composition. Together, these systems exemplify how advanced technology can be harnessed to solve persistent challenges in clinical diagnostics. The integration of these innovations into wearable devices is poised to offer a practical, everyday application that can change how routine health monitoring is conducted.
Know Labs (NYSE: KNW) has announced successful laboratory research using its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify real-time pH level changes. The research demonstrates a novel contactless approach where the sensor detects changes through a PVC pipe using Linear Discriminant Analysis and Fourier transform of frequency data.
The technology shows promising applications across multiple sectors:
- Medical Diagnostics: For monitoring physiological states and managing health conditions through pH measurements in blood, urine, saliva, and cerebrospinal fluid
- Pharmaceutical Manufacturing: Essential for drug formulation, production processes, and final product testing
- Food Safety and Quality: Critical for controlling product taste, texture, color, shelf-life, and preventing harmful microorganism growth
The company has submitted this research for peer review and launched Know Labs Technology Licensing (KTL) program to enable corporations, universities, and research institutions to utilize RFDS technology across various industries.
Know Labs (NYSE American: KNW) has announced its participation in The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair, scheduled for March 19-22, 2025, in Amsterdam, Netherlands. The company, which specializes in non-invasive medical diagnostic technology through its Radio Frequency Dialectic Spectroscopy (RFDS) platform, will present updates on their non-invasive blood glucose monitor development since the previous year's conference.
The company plans to engage with potential strategic partners and industry leaders in diabetes management to explore collaboration opportunities. Following the recent launch of Know Labs Technology Licensing (KTL), the company has established a clear pathway for partnership and licensing arrangements, aimed at accelerating the commercialization of their platform technology.
Know Labs (KNWN) has announced the cancellation of its Special Meeting of Stockholders that was scheduled for March 7, 2025. The meeting was originally intended to seek approval for a reverse stock split. This cancellation follows the company's recent implementation of a 1-for-40 reverse stock split of its authorized and outstanding common stock on February 18, 2025, which became effective February 19, 2025. The company noted that this reverse split did not require stockholder approval.
Know Labs, which recently moved from NYSE American (KNW) to OTC Pink Markets (KNWN), is known for its work in radio frequency dielectric spectroscopy (RFDS) technology.
Know Labs (KNWN) has announced a 1-for-40 reverse stock split of its common stock, effective February 19, 2025. The company's stock will temporarily trade under 'KNWND' for 20 days before reverting to 'KNWN' on the OTC Pink Market. This move follows the company's delisting from NYSE American due to bid prices falling below $0.10.
The company is currently appealing the delisting decision to the NYSE American Listings Qualifications Panel, with trading suspended during the appeal process. The reverse split was implemented by the Board of Directors as part of efforts to regain NYSE American listing compliance. The company expects near-term revenues from its recently announced Know Labs Technology Licensing initiative while continuing its focus on blood glucose monitoring development.
Know Labs (KNWN) reported Q1 FY2025 financial results, showing a net loss of $4.67 million, up 35.4% from $3.45 million in Q1 FY2024. The company recorded a non-cash charge of $2.45 million related to stock-based compensation, debt extinguishment, warrant repricing, and debt issuance costs.
R&D expenses decreased 46.1% to $802,000, while SG&A expenses dropped 2% to $1.97 million. Cash and equivalents stood at $1.03 million as of December 31, 2024, down from $3.11 million on September 30, 2024. The company closed a $300,000 registered direct offering and believes it has sufficient funds to operate until April 30, 2025.
Shareholder equity was negative $3.91 million, and the company's auditors included a going concern warning in their opinion.
Know Labs (KNWN) has announced it will host a webcast on February 14, 2025, at 1:30 PM PT to discuss its first quarter fiscal year 2025 business updates and financial results for the period ended December 31, 2024. The company, which recently moved from NYSE American to OTC Markets, specializes in radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and has launched the Know Labs Technology Licensing (KTL) initiative.
The live audio webcast will be accessible to media and investors at https://ir.knowlabs.co starting at 1:15 PM PT, with a replay available afterward on the company's website.
Know Labs (KNWN) has filed an appeal against NYSE American's decision to delist the company due to its stock price falling below $0.10. During the appeal process, trading of Know Labs stock on NYSE American will be suspended, and the company has transitioned to trading on the OTC Markets under the symbol 'KNWN' effective January 29, 2025.
The company, which specializes in radio frequency dielectric spectroscopy (RFDS), recently initiated a licensing program through Know Labs Technology Licensing (KTL) and continues to advance its proprietary technology. Their primary focus remains on developing non-invasive diagnostics, particularly blood glucose monitoring, which will require FDA clearance before market introduction.
CEO Ron Erickson emphasized that despite the NYSE situation, the company has successfully reduced overhead, received peer-reviewed recognition, and maintains optimism about near-term licensing opportunities and revenue generation.
Know Labs (NYSE American: KNW) announced that NYSE Regulation is initiating delisting proceedings due to the company's bid price falling under $.10, according to Section 1003(f)(v) of the NYSE American Company Guide. The company's stock will be suspended from NYSE American trading while Know Labs works on compliance measures and appeals the delisting determination.
Effective January 29, 2025, the company's stock will trade on the OTC Markets under the symbol 'KNWN'. CEO Ron Erickson emphasized that this development comes at a time when the company has initiated a licensing program, received peer-reviewed recognition, reduced overhead, and continued advancing its proprietary radio frequency dielectric spectroscopy (RFDS) technology. The company maintains its focus on developing non-invasive diagnostics, particularly blood glucose monitoring.
Know Labs (NYSE: KNW) has announced the formation of Know Labs Technology Licensing (KTL), a new business unit dedicated to licensing its radio frequency dielectric spectroscopy (RFDS) technology. Modeled after Qualcomm Technology Licensing, KTL aims to expand the application of RFDS beyond medical diagnostics into various industries including industrial processes, consumer electronics, automotive, and IoT networks.
The initiative emerged following significant third-party interest after the company's Skunkworks announcement in May 2024. KTL will provide Software Development Kits and RFDS test automation products to licensing partners. An early example includes the development of a 'smart steering wheel' for automotive safety applications.
While Know Labs maintains its focus on non-invasive medical diagnostics, particularly blood glucose monitoring, KTL will enable external partners to integrate RFDS technology across different sectors, potentially creating new revenue streams through licensing agreements.
Know Labs (NYSE: KNW) has announced a registered direct offering priced at-the-market, raising $300,000 in gross proceeds before deducting fees and expenses. The offering consists of units, each comprising one share of stock and one warrant at $0.24 per unit. The warrants are exercisable at $0.24 and will expire after five years, featuring a cashless exercise option under certain circumstances.
The offering is being conducted under the company's effective shelf registration statement on Form S-3, which was filed with the SEC on December 22, 2023, and declared effective on January 11, 2024. A prospectus supplement dated December 13, 2024, has been filed to complement the base prospectus.
FAQ
What is the current stock price of Know Labs (KNW)?
What is the market cap of Know Labs (KNW)?
What core technologies power Know Labs Inc's diagnostic solutions?
How do Know Labs' technologies improve patient care?
What is the primary business focus of Know Labs Inc?
In which industry does Know Labs Inc operate?
How does Know Labs differentiate itself from traditional diagnostic methods?
What potential applications arise from Know Labs' wearable diagnostic technology?
